People of European ancestry tend to receive greater benefit from anticancer treatments than people of African ancestry. The recent attention on these different outcomes in patients globally with cancer is uncovering potential sources for these biases as significantly poor representation persists for Blacks when using cell line models. Similar observations are seen at the clinical level. To close the gaps and to ensure equal benefit for both Blacks and Whites with cancers, increased representation of cell lines needs to be achieved. A focused push from funding agencies, journal editors and policymakers can aid in this outcome. 

Read the article here

Categories

Cancer  

Tags

cancer  cell lines  diversity  

Reply

Please Sign in (or Register) to view further.